JASMINE NAZARI: Open Payments
NPI 1396311205 · RANCHO CUCAMONGA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,271 in 86 payments from 16 companies in 2025. Trend: 2023 $561 · 2024 $707 · 2025 $2,271
Food & beverage: $2,171Education: $100
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 29 | $481 |
| Incyte Corporation | 16 | $445 |
| GENZYME CORPORATION | 8 | $333 |
| ABBVIE INC. | 4 | $157 |
| UCB, Inc. | 3 | $157 |
| Novartis Pharmaceuticals Corporation | 6 | $140 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $100 |
| Janssen Biotech, Inc. | 4 | $92 |
| Lilly USA, LLC | 3 | $71 |
Products named: DUPIXENT, NEMLUVIO, OPZELURA, SKYRIZI, Bimzelx, COSENTYX, TREMFYA, TALTZ.
Industry payments across CA — which companies pay providers there.
